{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=27&sponsor=Boehringer+Ingelheim",
    "query": {
      "sponsor": "Boehringer Ingelheim",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 673,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=28&sponsor=Boehringer+Ingelheim&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=26&sponsor=Boehringer+Ingelheim&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T21:25:07.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06745284",
      "title": "A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Survodutide",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2025-03-26",
      "completion_date": "2027-01-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06745284"
    },
    {
      "nct_id": "NCT06006585",
      "title": "A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "BI 771716",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-10-06",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 9,
      "location_summary": "Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06006585"
    },
    {
      "nct_id": "NCT02423525",
      "title": "Safety Study of Afatinib for Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santosh Kesari",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-12",
      "completion_date": "2021-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423525"
    },
    {
      "nct_id": "NCT01690624",
      "title": "BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "BI 836858",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-09-13",
      "completion_date": "2018-05-21",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01690624"
    },
    {
      "nct_id": "NCT05327946",
      "title": "A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BI 770371",
          "type": "DRUG"
        },
        {
          "name": "ezabenlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2022-05-17",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 2,
      "location_summary": "Sarasota, Florida • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05327946"
    },
    {
      "nct_id": "NCT03697304",
      "title": "Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasm Metastasis",
        "Advanced Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Ezabenlimab",
          "type": "DRUG"
        },
        {
          "name": "BI 754111",
          "type": "DRUG"
        },
        {
          "name": "BI 836880",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2019-03-19",
      "completion_date": "2024-12-03",
      "has_results": true,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03697304"
    },
    {
      "nct_id": "NCT00281593",
      "title": "Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Telmisartan",
          "type": "DRUG"
        },
        {
          "name": "Ramipril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1354,
      "start_date": "2006-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 70,
      "location_summary": "Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281593"
    },
    {
      "nct_id": "NCT04876391",
      "title": "A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Spesolimab 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Spesolimab 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching 600 mg Spesolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching 1200 mg Spesolimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2021-08-24",
      "completion_date": "2024-04-26",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04876391"
    },
    {
      "nct_id": "NCT06321302",
      "title": "A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "BI 764524",
          "type": "DRUG"
        },
        {
          "name": "Sham comparator to BI 764524",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept (Eylea®) - US only",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2024-05-15",
      "completion_date": "2027-08-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06321302"
    },
    {
      "nct_id": "NCT01358864",
      "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon-alpha (IFN)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 678,
      "start_date": "2011-06",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-10-16T21:25:07.463Z",
      "location_count": 18,
      "location_summary": "North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more",
      "locations": [
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358864"
    }
  ]
}